Trial Profile
First-Line Dasatinib or Nilotinib Followed by Response Guided Switch to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 01 Nov 2018 Status changed from recruiting to discontinued.
- 19 Oct 2016 Planned End Date changed from 1 Mar 2024 to 1 Oct 2023.
- 19 Oct 2016 Planned primary completion date changed from 1 Mar 2020 to 1 Oct 2019.